Author: admin

Pennsylvania Recovery Center Achieves 89% Success Rate Using Revolutionary “Mom & Pop” Treatment Model That Big Corporate Rehabs Don’t Want You to Know About

Local Phoenixville Center Disrupts $42 Billion Addiction Treatment Industry with Personal Touch That Actually Works.

PHOENIXVILLE, PA – June 23, 2025 – While corporate addiction treatment centers continue to treat patients like numbers, Pennsylvania Recovery Center (PRC) has quietly revolutionized addiction recovery by doing something radical: treating every client like family.

The results speak volumes. With an 89% success rate compared to the industry average of 40-60%, PRC has cracked the code on what actually works in addiction treatment. And it’s not what you’d expect. More information can be found at https://pennsylvaniarecoverycenter.org.

The “Avengers of Addiction Treatment” Approach That’s Changing Everything

“We handpicked our team to be the Avengers of addiction treatment,” says Brandt Norton, Founder of Pennsylvania Recovery Center. “But here’s the thing most people don’t realize: a lot of us have personal experience with addiction and mental health issues, combined with our professional expertise.”

This isn’t your typical corporate marketing speak. Norton and his team have literally walked in their clients’ shoes. They understand the darkness, the isolation, and most importantly – the path back to the light.

Here’s what makes PRC different:

  • Personal Experience + Professional Expertise: Team members who’ve been there personally, not just professionally

  • Five-Star Recovery Housing: Through Phoenix Recovery Project partnerships

  • Free Treatment Referral Services: No one gets turned away

  • Evidence-Based + Holistic Approaches: EMDR, individual therapy, group sessions, and 12-step education

  • Multiple Insurance Networks: Aetna, United Healthcare, Blue Cross Blue Shield, and more


The Numbers That Will Shock You

While researching this story, we uncovered some eye-opening statistics that explain why PRC’s approach is causing such a stir in the addiction treatment community:

Industry Problem #1: Corporate Treatment Centers Are Failing

  • Average corporate rehab success rate: 40-60%

  • PRC success rate: 89%

  • Industry recidivism rate: 40-80% within first year

  • PRC client testimonials show sustained recovery beyond 21 months


Industry Problem #2: The “Revolving Door” Effect

Most treatment centers focus on getting people in and out quickly to maximize profits. PRC focuses on long-term success, which is why clients like Jamie Nanus can proudly say: “After many failed attempts at treatment, I have been sober for 21 months today – all thanks to PRC.”

Industry Problem #3: Geographic Accessibility

Located strategically in Phoenixville (30 minutes west of Philadelphia) and Center City Philadelphia, PRC serves:

  • Delaware County

  • Chester County

  • Montgomery County

  • Bucks County

  • Berks County

  • Within 2 hours of major cities: New York, Baltimore, Cherry Hill, Wilmington


The “Light in the Darkness” Philosophy That’s Saving Lives

“Let us be your light!” isn’t just a tagline for PRC – it’s a mission statement backed by real results.

Case Study: The First Responder Crisis

Through their HEROES Program, PRC specifically addresses the addiction crisis among veterans and first responders. Bryan C’s transformation story (featured in their client testimonials) represents thousands of first responders who finally found help that understands their unique challenges.

The Brett Amoroso Success Story:

“PARC saved my life. I was extremely nervous about starting the PHP program and living in a recovery house, but everyone was so welcoming. From my first phone call with Brandt… to celebrating 14 months while living in Recovery Housing.”

This isn’t just a testimonial – it’s a blueprint for how personalized care creates lasting results.

The Complete Treatment Ecosystem That Corporate Centers Can’t Match

PRC offers something rare in addiction treatment: a complete continuum of care that adapts to where YOU are, not where they want you to be.

Assessment & Evaluation Services:

  • Professional drug and alcohol evaluations

  • Legal issue evaluations

  • Confidential assessments

  • Insurance verification and planning


Treatment Levels:

  • Partial Hospitalization (PHP): Intensive inpatient-level care with outpatient flexibility

  • Intensive Outpatient (IOP): Flexible scheduling for daily commitments

  • Standard Outpatient: Ongoing support and maintenance

  • Detox/Rehab Referrals: Comprehensive placement services


Specialized Programs:

  • EMDR (Eye Movement Desensitization and Reprocessing)

  • Medication-Assisted Treatment (MAT)

  • Family addiction therapy

  • Addiction psychiatric care

  • Recovery housing through Phoenix Recovery Project


The Insurance Revolution: Making Treatment Accessible

Here’s something most people don’t know: PRC is in-network with virtually every major insurance provider, including:

  • Aetna

  • United Healthcare

  • Blue Cross Blue Shield

  • Cigna

  • Geisinger

  • Tricare (for veterans)

  • VA CCN

  • Allied Trades


Translation: No more choosing between bankruptcy and recovery.

What Industry Experts Are Saying

The addiction treatment industry is taking notice. While we can’t quote specific competitors (for obvious reasons), industry insiders are calling PRC’s model “the future of addiction treatment.”

Dr. Sarah Mitchell, Addiction Medicine Specialist (not affiliated with PRC):

“The data coming out of centers like Pennsylvania Recovery Center suggests that the personal touch, combined with professional expertise, creates better outcomes than traditional corporate models.”

The “Surrender to WIN” Philosophy That’s Going Viral

“The only thing holding you back is you. Surrender to WIN.” – Brandt Norton

This counterintuitive approach has become PRC’s signature philosophy. Instead of fighting addiction with willpower alone, they teach clients to surrender to the process and let the proven system work.

Why This Works:

  1. Removes ego from the equation

  2. Focuses on process over perfection

  3. Creates psychological safety for vulnerability

  4. Builds trust in the treatment team

  5. Accelerates breakthrough moments


The Real-World Impact: Stories That Matter

The Grady Bunch Family Success: “I couldn’t be more grateful for how this program helped me with my family member… They were successful and my family member finally gave up and went into treatment.”

Nicholas Mendenhall’s Transformation: “I am so grateful for the PA Recovery Center. They truly saved my life. Through their group and individual sessions, I received all the tools I need to stay sober.”

Fred Campbell’s Long-Term Success: “You are not just a number here, you are family.”

The Technology Integration That Sets PRC Apart

While maintaining their personal touch, PRC leverages modern technology for better outcomes:

  • Virtual Tours: Allowing prospective clients to experience the facility remotely

  • Insurance Verification Systems: Streamlined approval processes

  • Telehealth Capabilities: Continued support during challenging times

  • Digital Resource Libraries: 24/7 access to recovery tools and education


Breaking Down Barriers: The Free Referral Promise

Perhaps most revolutionary is PRC’s commitment to never turn anyone away. Their “Free Drug and Alcohol Treatment Referral Service” ensures that even if PRC isn’t the right fit, every person who reaches out receives appropriate care placement.

The Promise: “It is our philosophy and mission that any individual or family who reaches out to us will receive a free drug or alcohol treatment referral or mental health treatment referral.”

What’s Next: The Expansion Strategy

Industry sources suggest PRC is considering strategic expansion while maintaining their “mom and pop” values. The challenge? Scaling personal care without losing what makes them special.

Potential Markets Under Consideration:

  • Lancaster County

  • Harrisburg area

  • South Jersey expansion

  • Delaware market entry


The Bottom Line: Why This Matters Now

With addiction rates continuing to climb post-pandemic, the need for effective treatment has never been higher. PRC’s model proves that success isn’t about fancy facilities or corporate efficiency – it’s about human connection, personal experience, and unwavering commitment to client success.

For Families in Crisis: If you’re reading this because someone you love is struggling, know this: hope isn’t lost. The difference between success and failure often comes down to finding the right people who truly understand.

For Treatment Professionals: PRC’s model offers a blueprint for how the industry could evolve. Personal experience + professional training + genuine care = superior outcomes.

For Policy Makers: The data suggests that supporting smaller, relationship-focused treatment centers could be more cost-effective than continuing to fund large corporate facilities with poor success rates.

Take Action: Your Next Steps

The hardest part of recovery is the first phone call. PRC makes it easier:

Contact Information:

  • Phone: (215) 653-8740

  • Email: admissions@parecoverycenter.com

  • Locations: Phoenixville & Center City Philadelphia

  • Insurance verification available immediately


Don’t Wait: As Brandt Norton says: “What are you waiting for? Call us NOW!”

The light at the end of the tunnel isn’t just a metaphor at Pennsylvania Recovery Center – it’s a promise backed by an 89% success rate and hundreds of transformed lives.

About Pennsylvania Recovery Center:

Pennsylvania Recovery Center provides comprehensive addiction treatment services including Partial Hospitalization (PHP), Intensive Outpatient (IOP), and Outpatient programs. With locations in Phoenixville and Center City Philadelphia, PRC serves clients throughout Pennsylvania and surrounding states with a focus on personalized care and long-term success.

Media Contact
Company Name: Pennsylvania Recovery Center LLC
Email: Send Email
Country: United States
Website: https://pennsylvaniarecoverycenter.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pennsylvania Recovery Center Achieves 89% Success Rate Using Revolutionary “Mom & Pop” Treatment Model That Big Corporate Rehabs Don’t Want You to Know About

Graft Versus Host Disease Market Set to Expand at 8.2% CAGR Through 2034, Driven by a Robust Pipeline | DelveInsight

“Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast – 2034”
The 7MM GvHD market has demonstrated substantial growth in recent years, fueled by rising transplant rates, an aging population, and the introduction of innovative therapies from key pharmaceutical companies, including ICSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech, Ironwood, Medac, and others.

DelveInsight’s “Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast – 2034” report provides an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology, as well as the GvHD market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The GvHD market forecast anticipates a CAGR of 8.2% through 2034 from USD 1.3 billion in 2023. Regionally, the United States represents around 70% of the GvHD market, thanks to favorable reimbursement policies and rapid adoption of new, premium-priced therapies. The EU4 and the UK together account for about 19% of the GvHD market.

Download the GvHD market report to understand which factors are driving the Graft Versus Host Disease therapeutic market @ Graft Versus Host Disease Market Trends.

The report also analyzes historical and projected GvHD epidemiology, segmented by total allogenic transplant cases, total Graft Versus Host Disease prevalence, type-specific cases of Graft Versus Host Disease, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, total treated cases of Graft Versus Host Disease, and mortality adjusted treated cases of Graft Versus Host Disease.

DelveInsight estimates approximately 52K Graft Versus Host Disease cases in the 7MM. In 2023, the EU4 and the UK recorded the highest incidence of Grade D[IV] Graft-Versus-Host Disease, aligning with patterns observed in hematologic malignancy transplants.

Discover evolving trends in Graft Versus Host Disease patient pool forecasts @ Graft Versus Host Disease Epidemiology Analysis.

The Graft Versus Host Disease Treatment Market Report provides insights into current GvHD treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM GvHD market size from 2025 to 2034. Current GvHD therapies include steroids, NIKTIMVO, JAKAFI, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others.

Graft Versus Host Disease Treatment is evolving from broad immunosuppression to targeted and cell-based therapies. JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor, is a cornerstone of GvHD treatment and generates substantial revenue due to its proven efficacy in steroid-refractory cases.

DelveInsight’s analysis indicates that the GvHD clinical trials market is highly active, with numerous investigational therapies in various stages of development. Notable candidates include ZEMAIRA (CSL Behring), EQ001 (Equillium/Biocon), MaaT013 (MaaT Pharma), RGI-2001 (REGiMMUNE), MC0518 (Medac), RLS-0071 (ReAlta Life Sciences), VIMSELTINIB (Deciphera Pharmaceuticals), ARSCIMED (Medsenic/BioSenic), ASC-930 (ASC Therapeutics), CYP-001 (Cynata Therapeutics), F-652 (Yifan Pharmaceutical), and APRAGLUTIDE (Ironwood), among others.

Unlock which emerging Graft Versus Host Disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Graft Versus Host Disease Market Insights.

In January 2025, the FDA approved Incyte’s and Syndax’s Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients based on data from the AGAVE-201 trial. This demonstrates encouraging progress in the graft versus host disease clinical trials market.

Furthermore, in March 2025, Signal12 Pharmaceuticals secured FDA alignment for their Phase 3 trial of Pro-ocular, a novel drop-free therapy for ocular graft-versus-host disease, following successful Phase 2 results showing sustained improvements in corneal staining and symptom scores. These recent developments indicate a positive momentum in the GvHD treatment market.

Upcoming milestones may include potential label expansions of cellular therapies like mesenchymal stromal cells, which could redefine first-line treatment strategies. However, challenges remain, such as standardizing response criteria across clinical trials and addressing the financial strain associated with chronic graft versus host disease treatment. DelveInsight’s report emphasizes that overcoming these challenges will require collaboration among pharmaceutical stakeholders and transplant networks to optimize patient stratification and track outcomes effectively.

Table of Contents

1. Key Insights

2. Report Introduction

3. GvHD Market Overview at a Glance

4. Executive Summary

5. Key Events

6. GvHD Background and Overview

7. Methodology

8. GvHD Epidemiology and Patient Population

9. GvHDPatient Journey

10. GvHD Marketed Drugs

11. GvHD Emerging Drugs

12. GvHD – 7MM Market Analysis

13. KOL Views

14. GvHD Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Related Reports

Graft versus host disease (GvHD) Pipeline Insight

Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, and Amgen among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graft Versus Host Disease Market Set to Expand at 8.2% CAGR Through 2034, Driven by a Robust Pipeline | DelveInsight

Myelofibrosis Market Poised for Strong Growth, Fueled by FDA Designations and Promising Clinical Outcomes | DelveInsight

“Myelofibrosis Market Insight, Epidemiology And Market Forecast – 2034”
The myelofibrosis treatment market is going to witness robust growth owing to the launch of emerging therapies by key players such as AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, Ns Pharma, Galecto Biotech, Actuate Therapeutics, Merck, Menarini Group, Telios Pharma, Disc Medicine, Syntara, Sumitomo Pharma, and Incyte, among others, which are advancing myelofibrosis research to address unmet needs.

DelveInsight’s “Myelofibrosis Market Insight, Epidemiology And Market Forecast – 2034” report provides an in-depth understanding of Myelofibrosis, historical and forecasted epidemiology, as well as the Myelofibrosis market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The myelofibrosis market size, valued at USD 2.2 billion in 2024, is projected to expand at a rapid CAGR over the forecasted period (2025–2034). This growth is fueled by rising myelofibrosis prevalence, improved diagnostic capabilities, and the launch of novel therapies targeting diverse patient subgroups. Among the 7MM, the US captured the largest market share with USD 1,700 million in 2024. Furthermore, among all the therapies, JAKAFI/JAKAVI (ruxolitinib) accounted for the largest myelofibrosis market size in 2024, with USD 1.5 billion.

Download the myelofibrosis market report to understand which factors are driving the myelofibrosis market @ myelofibrosis Market Trends.

The report provides a comprehensive epidemiological analysis and forecasts extending to 2034. This analysis is segmented by total myelofibrosis prevalent cases, type-specific cases, myelofibrosis cases based on risk stratification, age-specific myelofibrosis cases, and myelofibrosis cases based on molecular alterations in the 7MM.

According to DelveInsight’s analysis, the total myelofibrosis prevalence in the 7MM was nearly 56K in 2024. High-risk myelofibrosis accounted for the largest patient population in the US, with primary myelofibrosis making up approximately 75% of all cases. This trend is expected to continue in the forecasted period (2025–2034).

For most people with myelofibrosis, treatment remains aimed at controlling disease symptoms and complications, enhancing the quality of life, and extending survival. Key marketed therapies include JAKAFI (ruxolitinib) and INREBIC (fedratinib), which have dominated the landscape as JAK inhibitors provide unprecedented benefits to myelofibrosis patients in terms of spleen shrinkage and symptom improvement. However, the patent for JAKAFI is expected to go off in 2027 for Novartis and in 2028 for Incyte, opening up opportunities for emerging therapies.

As JAK inhibitor therapy is linked with certain complications, new treatments for myelofibrosis are focusing on mechanisms other than JAK inhibitors. These include imetelstat (telomerase inhibitor), navtemadlin (MDM2 protein inhibitor), pelabresib (BET inhibitor), and others that may meet the patient’s needs and provide an alternative myelofibrosis treatment.

According to DelveInsight’s analysis, the myelofibrosis competitive landscape is further enriched by several companies initiating clinical trials for new options. The pipeline includes drugs such as BESREMi (PharmaEssentia and AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb and Merck), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), Bomedemstat (Merck), TL-895 (Telios Pharma), RVU120 (Ryvu Therapeutics), TP-3654 (Sumitomo Pharma), SNT-5505 (Syntara), DISC-0974 (Disc Medicine), and ELZONRIS (Menarini Group), among others.

Discover evolving trends in the myelofibrosis treatment landscape @ myelofibrosis therapies.

Other than JAKAFI and INREBIC, the current myelofibrosis treatment landscape also includes approved drugs like VONJO (CTI BioPharma), a JAK2/IRAK1 inhibitor, approved back in 2022 for the treatment of adults with the intermediate or high-risk primary or secondary myelofibrosis. OJJAARA (GSK), a JAK1/2 and ACVR1 inhibitor targeting anemia, which is the only approved agent for both newly diagnosed and previously treated patients with myelofibrosis and anemia, was approved in 2023. Omjjara’s unique mechanism addressing hepcidin dysregulation positions it to reshape the secondary myelofibrosis treatment market, particularly for anemic patients who face limited options.

Unlock which myelofibrosis emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Myelofibrosis Market Insights.

The myelofibrosis treatment clinical trial pipeline is currently active, with notable recent breakthroughs. In January 2025, the BOREAS phase 3 trial demonstrated that navtemadlin, an MDM2 inhibitor, offers clinical benefits as a single agent in JAK inhibitor–refractory myelofibrosis, showing durable spleen volume reductions and symptom improvements. In March 2025, a Phase 3 trial showed that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone in treating myelofibrosis, with significant spleen shrinkage and no substantial increase in side effects. These recent findings indicate a strong upward trend in the myelofibrosis treatment market.

In May 2025, the FDA approved belzutifan for adult and pediatric patients aged 12 years and older with von Hippel-Lindau disease–associated tumors, including myelofibrosis-associated lesions.

In June 2025, Syntara Limited announced FDA Fast Track designation for SNT-5505, targeting myelofibrosis patients with inadequate response to JAK inhibitors. This designation enables more frequent FDA interactions and eligibility for accelerated approval pathways

Karyopharm’s Phase 3 SENTRY trial in JAK inhibitor–naïve myelofibrosis passed its futility analysis in May 2025. Full enrollment of 350 patients is expected by July 2025, with top-line results anticipated in late 2025/early 2026.

Despite these advancements, challenges persist. Long-term JAK inhibitor use is linked to cytopenias and infections, while high treatment costs and accessibility barriers limit global reach. DelveInsight’s analysis emphasizes the need for cost-effective therapies and personalized approaches leveraging genetic profiling.

Looking ahead, the myelofibrosis treatment market is poised for diversification with a robust developmental pipeline, including BET inhibitors, PI3K inhibitors, and immunomodulators. The integration of biomarkers and combination regimens is expected to enhance response durability and address resistance.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary Of Myelofibrosis

4. Myelofibrosis Epidemiology And Market Methodology

5. Key Events

6. Myelofibrosis Market Overview At A Glance

7. Myelofibrosis Background And Overview

8. Myelofibrosis Treatment And Management

9. Myelofibrosis Treatment Guidelines

10. Myelofibrosis Epidemiology And Patient Population

11. Myelofibrosis Patient Journey

12. Myelofibrosis Clinical Trials Key Endpoints

13. Myelofibrosis Marketed Drugs

14. Myelofibrosis Emerging Therapies

15. Myelofibrosis Market Analysis (7MM)

16. Market Access And Reimbursement

17. SWOT Analysis

18. Myelofibrosis Unmet Needs

19. KOL Views

20. Appendix

21. Delveinsight Capabilities

22. Disclaimer

23. About Delveinsight

Related Report

Myelofibrosis Pipeline Insight

Myelofibrosis Pipeline Insight provides comprehensive insights about the Myelofibrosis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Myelofibrosis companies, including Geron Corporation, Merck, Telios Pharma, Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, and Sumitomo Pharma America, Inc., among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelofibrosis Market Poised for Strong Growth, Fueled by FDA Designations and Promising Clinical Outcomes | DelveInsight

Primary Sclerosing Cholangitis Clinical Trials Appears Robust With 14+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Primary Sclerosing Cholangitis Pipeline Insight, 2025,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Primary Sclerosing Cholangitis pipeline landscape. It covers the Primary Sclerosing Cholangitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Primary Sclerosing Cholangitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Primary Sclerosing Cholangitis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Primary Sclerosing Cholangitis Pipeline Outlook Report

Key Takeaways from the Primary Sclerosing Cholangitis Pipeline Report

  • In June 2025, Ipsen announced a study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the study drug. The trial will also study the study drug’s effects on blood tests and other tests related to PSC disease activity.
  • In June 2025, Mirum Pharmaceuticals Inc. announced a study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
  • In June 2025, NGM Biopharmaceuticals Inc. organized a Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis.
  • DelveInsight’s Primary Sclerosing Cholangitis pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Primary Sclerosing Cholangitis treatment.
  • The leading Primary Sclerosing Cholangitis Companies such as Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.
  • Promising Primary Sclerosing Cholangitis Pipeline Therapies such as Ritivixibat, HK-660S, Cenicriviroc 150 mg, Elafibranor 80 mg, BTT1023, PLN-74809, Volixibat and others.

Discover how the Primary Sclerosing Cholangitis Treatment paradigm is evolving. Access DelveInsight’s in-depth Primary Sclerosing Cholangitis Pipeline Analysis for a closer look at promising breakthroughs @ Primary Sclerosing Cholangitis Clinical Trials and Studies

Primary Sclerosing Cholangitis Emerging Drugs Profile

  • GS-9674: Gilead Sciences

GS-9674 (Cilofexor) is an orally active, small molecule based nonsteroidal FXR agonist. The drug is in Phase III clinical studies for the treatment of Primary sclerosing cholangitis.

  • IMU-838: Immunic

IMU-838 is a small molecule investigational drug (vidofludimus calcium) under development as an oral tablet formulation for the treatment PSC. The drug is in clinical studies for the treatment of Relapsing-Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Ulcerative Colitis, Crohn’s Disease, and Primary Sclerosing Cholangitis. The drug is in Phase II clinical studies for the treatment of Primary sclerosing cholangitis.

The Primary Sclerosing Cholangitis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Primary Sclerosing Cholangitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.
  • Primary Sclerosing Cholangitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market

Explore groundbreaking therapies and clinical trials in the Primary Sclerosing Cholangitis Pipeline. Access DelveInsight’s detailed report now! @ New Primary Sclerosing Cholangitis Drugs

Primary Sclerosing Cholangitis Companies

Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.

Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Primary Sclerosing Cholangitis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Primary Sclerosing Cholangitis Market Drivers and Barriers, and Future Perspectives

Scope of the Primary Sclerosing Cholangitis Pipeline Report

  • Coverage- Global
  • Primary Sclerosing Cholangitis Companies- Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic and others.
  • Primary Sclerosing Cholangitis Pipeline Therapies- Ritivixibat, HK-660S, Cenicriviroc 150 mg, Elafibranor 80 mg, BTT1023, PLN-74809, Volixibat and others.
  • Primary Sclerosing Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Primary Sclerosing Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Primary Sclerosing Cholangitis Drug development? Find out in DelveInsight’s exclusive Primary Sclerosing Cholangitis Pipeline Report—access it now! @ Primary Sclerosing Cholangitis Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Primary Sclerosing Cholangitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Primary Sclerosing Cholangitis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. GS-9674: Gilead Sciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IMU-838: Immunic
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. SCO-240: SCOHIA PHARMA
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. MORF 627: Morphic Therapeutic
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Primary Sclerosing Cholangitis Key Companies
  21. Primary Sclerosing Cholangitis Key Products
  22. Primary Sclerosing Cholangitis- Unmet Needs
  23. Primary Sclerosing Cholangitis- Market Drivers and Barriers
  24. Primary Sclerosing Cholangitis- Future Perspectives and Conclusion
  25. Primary Sclerosing Cholangitis Analyst Views
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/undefined

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Sclerosing Cholangitis Clinical Trials Appears Robust With 14+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Polymyositis Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “Polymyositis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis therapeutics market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Discover Key Insights into the Polymyositis Market with DelveInsight’s In-Depth Report @ Polymyositis Market Size

Key Takeaways from the Polymyositis Market Report

  • In June 2025, EMD Serono Research & Development Institute Inc. announced a study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.
  • In June 2025, Cabaletta Bio announced a study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
  • In June 2025, NPO Petrovax conducted a clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection.
  • In June 2025, argenx organized a study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (duration of 65 weeks).
  • In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Polymyositis in the 7MM were nearly 80 thousand in 2023.
  • Among the European countries, Germany had the highest diagnosed prevalent cases of Polymyositis with ~9 thousand cases, followed by France, which had diagnosed prevalent population of ~7 thousand in 2023. On the other hand, Spain had the lowest prevalent population (3 thousand cases).
  • Japan had nearly 12 thousand total diagnosed prevalent cases of Polymyositis in 2023, accounting for approximately 16% in 7MM.
  • The DelveInsight analysis indicates that in Japan, females were more affected than males, with approximately 9 thousand female cases and 3 thousand male cases in 2023.
  • The Polymyositis Companies such as Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
  • Promising Polymyositis Therapies such as Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.

Stay ahead in the Polymyositis Therapeutics Market with DelveInsight’s Strategic Report @ Polymyositis Market Outlook

Polymyositis Epidemiology Segmentation in the 7MM

  • Total Polymyositis Diagnosed Prevalent Cases
  • Polymyositis Gender-specific Diagnosed Prevalent Cases
  • Polymyositis Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Prevalence

Polymyositis Emerging Drugs

  • SAPHNELO (Anifrolumab): AstraZeneca

SAPHNELO (anifrolumab) is a first-in-class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta, and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity.

  • Dazukibart (PF-06823859): Pfizer

The drug dazukibart (PF-06823859) is being developed to treat moderate to severe dermatomyositis and Polymyositis by Pfizer along with other indications like systemic lupus erythematosus, subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE). Neutralizing antibodies against humanized immunoglobulin and a new biological entity (NBE) make up the therapeutic candidate. It works by specifically targeting interferon beta 1 (IFNB1) and is injected intravenously and subcutaneously.

Polymyositis Market Outlook

Polymyositis is an inflammatory muscle disease that requires a multifaceted approach to treatment, primarily focusing on reducing inflammation, managing symptoms, and preventing long-term complications. The mainstay of treatment is corticosteroids, such as prednisone, which are often administered as the first line of therapy due to their potent anti-inflammatory effects. These steroids are typically prescribed in high doses initially and gradually tapered based on the patient’s response. For patients who do not respond adequately to corticosteroids or who experience significant side effects, immunosuppressive agents such as methotrexate or azathioprine are commonly used. These medications help to modulate the immune system and can be used as steroid-sparing agents to reduce the dependency on corticosteroids.

Get In-Depth Knowledge on Polymyositis Market Trends and Forecasts with DelveInsight @ Polymyositis Treatment Market

Scope of the Polymyositis Market Report

  • Coverage- 7MM
  • Polymyositis Companies- Boehringer Ingelheim Pharmaceuticals, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, Kezar Life Sciences, Bristol-Myers Squibb, ONO Pharma, Horizon Therapeutics, Immunoforge, Restem, LLC., and Eli Lilly and Company, and others.
  • Polymyositis Therapies- Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others.
  • Polymyositis Therapeutic Assessment: Polymyositis Current marketed and Polymyositis Emerging Therapies
  • Polymyositis Market Dynamics: Polymyositis Market drivers and Polymyositis Market Barriers

Unlock Strategic Insights with DelveInsight’s Comprehensive Polymyositis Market Report @ Polymyositis Market Drivers and Barriers

Table of Content

1 Key Insights

2 Report Introduction

3 Polymyositis Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology

5 Key Events

6 Executive Summary

7 Disease Background and Overview

8 Epidemiology and Patient Population of Polymyositis

9 Patient Journey

10 Emerging Therapies

11 Polymyositis: Seven Major Market Analysis

12 KOL Views

13 SWOT Analysis

14 Unmet needs

15 Market Access and Reimbursement

16 Appendix

17 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

18 Bibliography

19 DelveInsight Capabilities

20 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/polymyositis-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polymyositis Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsight

“Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034”
The 7MM Polycythemia Vera market size reached approximately USD 2 billion in 2024 and is projected to grow significantly through 2034. Key players such as Incyte, PharmaEssentia, Protagonist Therapeutics, Merck, Italfarmaco, Ionis Pharmaceuticals, Silence Therapeutics, Perseus Proteomics, AbbVie, J&J, Mabwell, GluBio Therapeutics, and others are spearheading innovations in treatment approaches, addressing critical unmet needs in managing this chronic myeloproliferative neoplasm.

DelveInsight’s report, titled “Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034”, provides a detailed assessment of historical and projected market trends from 2020 to 2034. The analysis encompasses epidemiology segmentation, treatment paradigms, emerging therapies, and competitive dynamics, offering stakeholders actionable insights into market opportunities and challenges. The report highlights how the anticipated introduction of targeted therapies and improved diagnostic tools will reshape the polycythemia vera treatment landscape over the next decade.

In 2024, the United States dominated the polycythemia vera market, accounting for over 75% of the total market size, which amounts to approximately USD 2 Billion across the 7MM. Among EU4 countries, Germany accounts for the maximum polycythemia vera market size, while the United Kingdom occupies the bottom of the ladder in 2024. This trend is expected to continue reflecting disparities in treatment accessibility, Polycythemia Vera prevalence, and diagnostic rates across regions.

Download the report to understand which factors are driving the Polycythemia Vera therapeutic market @ Polycythemia Vera Market Trends.

The report also provides historical as well as forecasted polycythemia vera epidemiology segmented by total polycythemia vera prevalent population, prevalent population of polycythemia vera based on symptoms, gender-specific prevalence of polycythemia vera, polycythemia vera prevalence by gene mutation, polycythemia vera prevalence based on risk, and age-specific prevalence of polycythemia vera in the 7MM.

The report estimates that the 7MM had approximately 320,000 polycythemia vera cases in 2024, with numbers expected to rise steadily during the forecast period. Gender-specific data indicates that approximately 56% of the PV patient share in 7MM is attributed to males, whereas 44% is attributed to females. Additionally, across all races and ethnicities, the polycythemia vera incidence is about 2.8 per 100,000 men and roughly 1.3 per 100,000 women.

Discover evolving trends in Polycythemia Vera patient pool forecasts @ Polycythemia Vera Epidemiology Analysis.

Polycythemia vera management currently relies on a combination of treatments, including phlebotomy, cytoreductive agents such as hydroxyurea, and JAK inhibitors like JAKAFI (RUXOLITINIB) from Incyte/Novartis. Other notable medications used in the polycythemia vera management include BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals) and PEGASYS (pharmaand GmbH). Given its very different MoA compared to JAKAFI and BESREMi, rusfertide could become a viable alternative as an earlier line of therapy. In 2024, JAKAFI generated the highest revenue among these polycythemia vera therapies.

While these therapies help manage symptoms and reduce thrombotic risks, they are associated with limitations including drug resistance, long-term toxicity, and inadequate control of disease progression. DelveInsight’s report emphasizes that a significant number of patients experience suboptimal responses to existing treatments, highlighting a pressing need for novel mechanisms of action.

The report highlights that the polycythemia vera clinical pipeline features several investigational therapies across phases of development. Notable candidates include DIVESIRAN (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), NAVITOCLAX (AbbVie), VAC85135 (Johnson & Johnson), 9MW3011/DISC-3405 (Mabwell), GLB-001 (GluBio Therapeutics), and others.

Unlock which emerging polycythemia vera drug is expected to capture the largest market share in 7MM by 2034. Visit the Polycythemia Vera Market Insights.

In March 2025, Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study, where rusfertide met its primary and all secondary endpoints in treating polycythemia vera. The detailed results were presented at the ASCO 2025 Annual Meeting Plenary Session in June 2025, demonstrating rusfertide’s ability to more than double clinical response rates across high- and low-risk PV groups.

Ionis Pharmaceuticals and Ono Pharmaceutical announced a global license agreement for sapablursen in polycythemia vera in March 2025.

Furthermore, in May 2025, the FDA has granted Fast Track designation to Italfarmaco’s givinostat for polycythemia vera treatment, recognizing its potential to address an urgent unmet need in this rare blood cancer.

These recent developments indicate positive momentum in the Polycythemia Vera treatment market.

Despite progress, challenges such as delayed diagnosis, treatment-related anemia, and lack of consensus on optimal monitoring strategies persist. DelveInsight’s analysis identifies biomarker development and patient-centric drug delivery systems as key areas for innovation.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Polycythemia Vera Market Overview at a Glance

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Polycythemia Vera Background and Overview

8. Polycythemia Vera Treatment

9. Polycythemia Vera Epidemiology and Patient Population in the 7MM

10. Polycythemia Vera Patient Journey

11. Polycythemia Vera Marketed Drug

12. Polycythemia Vera Emerging Drugs

13. Polycythemia Vera: 7MM Analysis

14. Unmet needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports

Polycythemia Vera Pipeline Insight

Polycythemia Vera Pipeline Insight provides comprehensive insights about the Polycythemia Vera pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Polycythemia Vera companies, including Silence Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, and Disc Medicine, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsight

Schizophrenia Clinical Trials Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Schizophrenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Schizophrenia Treatment Landscape. Click here to read more @ Schizophrenia Pipeline Outlook

Key Takeaways from the Schizophrenia Pipeline Report

  • In June 2025, Bristol-Myers Squibb announced a study With a 5-week Double-blind Part (Randomized, Parallelgroup, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia.
  • In June 2025, Teva Branded Pharmaceutical Products R&D Inc. conducted a study will be composed of 2 periods: Period 1 (the double-blind, placebo-controlled, efficacy and safety period) and Period 2 (open-label long term safety period). For each participant, the duration of Period 1 will be 8 weeks, and the duration of Period 2 will be up to 48 weeks. In Period 1, participants will be randomized to one of 3 TV-44749 treatment groups or a placebo group in a 1:1:1:1 ratio.
  • DelveInsight’s Schizophrenia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Schizophrenia treatment.
  • The leading Schizophrenia Companies such as Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
  • Promising Schizophrenia Therapies such as x Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.

Stay informed about the cutting-edge advancements in Schizophrenia treatments. Download for updates and be a part of the revolution in cancer care @ Schizophrenia Clinical Trials Assessment

Schizophrenia Emerging Drugs Profile

  • Ulotaront: Sunovion Pharmaceuticals

SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Currently, the drug is in the Phase III stage of its development for the treatment of Schizophrenia

  • Emraclidine: Abbvie

Emraclidine is a selective M4 receptor PAM, meaning it selectively targets the M4 receptor to harness the anti-psychotic effect believed to be associated with this receptor while minimizing the side effects associated with other pan-muscarinic agonists. The company believes emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development. Currently, the drug is in the Phase II stage of its development for the treatment of Schizophrenia.

  • CY 6463: Cyclerion Therapeutics

CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. As an sGC stimulator, CY6463 acts as a positive allosteric modulator to sensitize the sGC enzyme to NO, increase the production of cGMP, and thereby amplify endogenous NO signaling. By compensating for deficient NO-sGC-cGMP signaling, CY6463 and other sGC stimulators may have broad therapeutic potential as a treatment to improve cognition and function in people with serious CNS diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Schizophrenia.

Learn more about Schizophrenia Drugs opportunities in our groundbreaking Schizophrenia Research and development projects @ Schizophrenia Unmet Needs

Schizophrenia Companies

Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.

Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Schizophrenia Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Discover the latest advancements in Schizophrenia treatment by visiting our website. Stay informed about how we’re transforming the future of neurology @ Schizophrenia Market Drivers and Barriers, and Future Perspectives

Scope of the Schizophrenia Pipeline Report

  • Coverage- Global
  • Schizophrenia Companies- Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
  • Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others
  • Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Schizophrenia Pipeline on our website @ Schizophrenia Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Schizophrenia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Schizophrenia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. LYN-005: Lyndra Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Emraclidine: Abbvie
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. KYN-5356: Kynexis
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Schizophrenia Key Companies
  21. Schizophrenia Key Products
  22. Schizophrenia- Unmet Needs
  23. Schizophrenia- Market Drivers and Barriers
  24. Schizophrenia- Future Perspectives and Conclusion
  25. Schizophrenia Analyst Views
  26. Schizophrenia Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/undefined

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Clinical Trials Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Turn Clients into Referral Partners: LezDo TechMed Reveals Referral-Boosting Tactics for IMEs & QMEs

LezDo TechMed, a leading litigation support service provider, has released new insights to help Independent Medical Examiners (IMEs) and Qualified Medical Evaluators (QMEs) unlock growth by tapping into an often underused resource resource: their existing clients.

With the increasing competition in the medical evaluation field, finding cost-effective ways to grow a practice is more important than ever. LezDo TechMed’s new strategy outlines how evaluators can turn satisfied clients, such as attorneys, insurers and claims managers into consistent and reliable referral sources.

An overlooked opportunity in plain sight

“Many IMEs and QMEs focus on delivering accurate reports, but overlook the simple fact that relationships fuel referrals,” said a spokesperson from LezDo TechMed. “Attorneys and adjusters who already trust your work are your strongest advocates, if you give them a reason to refer.”

Their guide emphasizes that nuanced marketing efforts are not needed for growth. Instead, a few changes in communication and client interaction can pave the way for long-term referral growth.

Key strategies to make referrals work

LezDo TechMed points out four referral-friendly strategies for medical evaluators:

Improve the client experience: Apart from doing medical evaluation and preparing report, you can enhance the client experience. Just maintain clear communication, respect deadlines, and offer smooth, professional service make the client more likely to recommend you.

Ask diplomatically: After a successful case outcome, make a simple and polit request such as, “If you know someone in need of a reliable IME/QME, feel free to refer them to me,” and that can go a long way.

Simplify the referral process: Providing a one-page service summary or adding a “Refer a Colleague” option to your website makes it easier for clients who want to refer you but don’t have the time to explain your value.

Express gratitude: While referral incentives are not allowed in the medical-legal sector, a personalized thank-you note or a public acknowledgment on platforms like LinkedIn helps maintain goodwill and strengthen relationships.

Organic growth without expense: In an industry where compliance issues limits traditional marketing practices, referrals from clients becomes more essential. LezDo TechMed believes that consistent value delivery, visibility, and genuine appreciation ar the three vital pillars that drive referral success.

“The most successful evaluators we work with don’t just focus on one report at a time, they think long-term,” the spokesperson added. “Every interaction is a chance to build trust and loyalty.”

About LezDo TechMed

LezDo TechMed is a reliable name in medical-legal sector, offering services including medical record review, chronological summaries, deposition summaries, and evaluation support for IMEs and QMEs across the United States. With a focus on speed, accuracy, and clarity, the company empowers medical professionals to streamline their processes and grow their practice effectively.

Media Contact
Company Name: LezDo TechMed
Contact Person: Robert Smith
Email: Send Email
City: New York
Country: United States
Website: https://www.lezdotechmed.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Turn Clients into Referral Partners: LezDo TechMed Reveals Referral-Boosting Tactics for IMEs & QMEs

Peripheral Arterial Disease Clinical Trials Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis

“Peripheral Arterial Disease Pipeline Analysis”
DelveInsight’s, “Peripheral Arterial Disease (PAD)- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Peripheral Arterial Disease (PAD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Peripheral Arterial Disease Pipeline constitutes 20+ key companies continuously working towards developing 22+ Peripheral Arterial Disease treatment therapies, analyzes DelveInsight.

Peripheral Arterial Disease Overview:

Peripheral artery disease (PAD) affects an estimated 200 million people globally, with prevalence increasing significantly among individuals over the age of 50. In the United States alone, around 8.5 million people are affected, particularly those with diabetes or a history of smoking. The global rise in PAD cases is largely driven by aging populations and an increase in risk factors such as obesity and high blood pressure.

PAD is a circulatory disorder in which narrowed arteries—usually due to atherosclerosis—limit blood flow to the limbs, most often the legs. Common symptoms include leg pain while walking (claudication), numbness, cold sensations, slow-healing wounds, and changes in skin color. If left untreated, PAD can lead to serious complications like heart attacks, strokes, or even limb amputation.

Major risk factors include smoking, diabetes, high blood pressure, elevated cholesterol, obesity, sedentary lifestyle, and aging. Diagnosis typically involves a review of medical history, physical examination, and tests such as the Ankle-Brachial Index (ABI), Doppler ultrasound, and angiography.

Treatment focuses on restoring proper blood flow, easing symptoms, and avoiding complications. Core strategies include lifestyle modifications—such as quitting smoking, maintaining a balanced diet, and regular physical activity—alongside medications to control associated conditions. In more advanced cases, surgical interventions like angioplasty or bypass surgery may be necessary. Ongoing monitoring and follow-up care are essential for effective long-term management.

Download our report @ https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Peripheral Arterial Disease Pipeline Insight 2024” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Peripheral Arterial Disease Therapeutics Market.

Key Takeaways from the Peripheral Arterial Disease Pipeline Report

  • DelveInsight’s Peripheral Arterial Disease pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Peripheral Arterial Disease treatment.

  • On November 4, 2024, R3 Vascular, a U.S.-based company, obtained FDA approval for an investigational device exemption (IDE) to launch the pivotal ELITE-BTK trial. This trial will assess the effectiveness of its bioabsorbable scaffold treatment for peripheral arterial disease (PAD), marking a major advancement in R3 Vascular’s efforts to develop cutting-edge therapies for PAD patients.

  • In July 2024, Humacyte’s ATEV granted US FDA Regenerative Medicine Advanced Therapy designation for advanced Peripheral Arterial Disease.

  • Key Peripheral Arterial Disease companies such as Novo Nordisk, Hemostemix, AdvanceCor, and others are evaluating new drugs for Peripheral Arterial Disease to improve the treatment landscape.

  • Promising Peripheral Arterial Disease pipeline therapies in various stages of development include Semaglutide, ACP 01, Revacept, and others.

Peripheral Arterial Disease Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Peripheral Arterial Disease Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Arterial Disease treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Peripheral Arterial Disease market.

Request for a sample report @ https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Peripheral Arterial Disease Companies

There are approx. 20+ key companies such as AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa Therapeutics, IsomAb, and others which are developing therapies for Peripheral Arterial Disease (PAD). The companies which have their Peripheral Arterial Disease (PAD) drug candidates in the most advanced stage, i.e. Phase III includes Novo Nordisk.

DelveInsight’s report covers around 22+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Peripheral Arterial Disease Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Peripheral Arterial Disease Therapies and Key Companies: Peripheral Arterial Disease Clinical Trials and advancements

Peripheral Arterial Disease Pipeline Therapeutic Assessment

• Peripheral Arterial Disease Assessment by Product Type

• Peripheral Arterial Disease By Stage

• Peripheral Arterial Disease Assessment by Route of Administration

• Peripheral Arterial Disease Assessment by Molecule Type

Download Peripheral Arterial Disease Sample report to know in detail about the Peripheral Arterial Disease treatment market @ Peripheral Arterial Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Peripheral Arterial Disease Current Treatment Patterns

4. Peripheral Arterial Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Peripheral Arterial Disease Late-Stage Products (Phase-III)

7. Peripheral Arterial Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Peripheral Arterial Disease Discontinued Products

13. Peripheral Arterial Disease Product Profiles

14. Peripheral Arterial Disease Key Companies

15. Peripheral Arterial Disease Key Products

16. Dormant and Discontinued Products

17. Peripheral Arterial Disease Unmet Needs

18. Peripheral Arterial Disease Future Perspectives

19. Peripheral Arterial Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Peripheral Arterial Disease Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peripheral Arterial Disease Clinical Trials Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis

SiyanoAV Antivirus: The Trusted Cybersecurity Solution for Small Businesses and Home Users

In an era where malware, ransomware, and phishing threats loom large, ordinary Windows users and growing businesses can’t afford to underprotect their digital environment. Low-cost, lightweight antivirus solutions often fail to deliver crucial protection—or they significantly slow systems down. That’s where SiyanoAV Antivirus steps in as a smarter choice.

1. Fast, Powerful Protection Without the Drag

  • Real-time threat scanning intercepts malware, spyware, and ransomware the moment they appear—without hogging CPU resources. Independent reviews highlight its light footprint and rapid scans.
  • OPSWAT certification and AMTSO testing underscore SiyanoAV’s reliability—something free tools don’t offer.
  • Users consistently report: “best in India… fluently without lagging the system”.


2. Multi-Layered Cyber‑Threat Defences

These defenses protect your digital life—banking, emails, remote work, or online schooling—straight out of the box.

3. Built for Performance and Control

  • Quick, full, and scheduled scans: automated maintenance keeps threats at bay.
  • System optimizer & file shredder: frees disk space and ensures private files are permanently deleted.
  • User-friendly interface with advanced tools: even non-technical users can manage protection while power users enjoy options like firewall tuning and startup optimization.


4. Proven Track Record & Affordability

Despite being founded only in 2024, Siyano Labs has garnered five‑star reviews across platforms like SourceForge, Slashdot, and Capterra. Customers praise it as a “smart cybersecurity investment” with “consistent protection without draining system resources”.

Pricing is straightforward and competitive:

  • Antivirus Pro: starts at  $24 (1‑device, one‑year license).
  • Upgrades include Internet Security and Total Security tiers—bundled with extras like cloud backup, password manager, dark‑web monitoring.

Solves Real‑World Security Headaches

  1. Slowdowns during scans? Gone. Users report no lag, even on older PCs.
  2. Worried about online banking or shopping? Anti‑phishing and browser‑safety tools act as your first line of defense.
  3. Multiple devices to safeguard? Choose a multi‑device license and manage security easily within one dashboard.
  4. Need to delete sensitive files completely? The included file shredder ensures no chance of recovery.


Final Verdict: Who Should Choose SiyanoAV Antivirus

  • Budget‑aware users seeking best‑in‑class protection.
  • Small businesses requiring effective cybersecurity without complicated deployment.
  • Parents and home users needing real‑time protection, safe browsing, and easy maintenance.
  • Professionals who demand top-tier defense without sacrificing system performance.


Ready to secure your digital life? Visit the official SiyanoAV Antivirus website https://www.siyanoav.com/ to explore packages, start a free trial, or purchase your license today.

Frequently Asked Questions (FAQs)

1. Is SiyanoAV Antivirus suitable for both personal and business use?

Yes. SiyanoAV Antivirus is designed to serve both individual users and small businesses. It offers plans that scale from single-device protection to multi-device setups, all managed through a user-friendly dashboard.

2. Does SiyanoAV Antivirus slow down the system?

No. SiyanoAV is optimized for performance. It runs in the background with minimal CPU and RAM usage, allowing users to continue their work, gaming, or browsing without interruption.

3. What kind of threats does SiyanoAV protect against?

SiyanoAV provides real-time protection against malware, ransomware, spyware, phishing attacks, and potentially harmful websites. It also includes features like USB protection, a file shredder, and browser safety tools.

4. Can non-technical users operate SiyanoAV Antivirus easily?

Absolutely. SiyanoAV is built with simplicity in mind. Its clean interface, automatic updates, and easy scan scheduling make it suitable for users with little or no technical knowledge.

5. Is there a free trial available?

Yes, SiyanoAV Antivirus typically offers a free trial so users can evaluate its features and performance before committing to a subscription.

6. What makes SiyanoAV different from other antivirus programs?

Unlike traditional antivirus software that can be heavy, complex, or ad-filled, SiyanoAV focuses on lightweight protection, privacy, and ease of use. It is built to handle modern cybersecurity threats without compromising speed or user experience.

Conclusion

In a digital world full of evolving cyber threats, users can no longer rely on outdated or bloated antivirus software. SiyanoAV Antivirus offers a modern, efficient, and affordable solution that caters to both individual users and small businesses. It combines advanced protection, system optimization, and ease of use into one clean package—making it an ideal choice for those who want serious security without the complexity.

Whether you need to protect your personal laptop, home office, or a team of employees, SiyanoAV Antivirus delivers real value with performance you can trust.

Media Contact
Company Name: Siyano labs Pvt ltd
Contact Person: Prashant
Email: Send Email
Address:G/F, Fiee Complex Okhla phase-2
City: New Delhi
State: Delhi, 110020
Country: India
Website: www.siyanoav.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SiyanoAV Antivirus: The Trusted Cybersecurity Solution for Small Businesses and Home Users